Suiqing Zhou | liver cancer | Best Researcher Award | 13333

Dr. Suiqing Zhou | liver cancer | Best Researcher Award 

Dr. Suiqing Zhou, Nanjing Medical University, China

Dr. Suiqing Zhou, a PhD student at Nanjing Medical University, is a clinician-scientist specializing in translational liver cancer research. With extensive experience in both clinical and basic science, Dr. Zhou has contributed significantly to hepatocellular carcinoma studies, serving as a key investigator in multiple national and provincial research projects. Their work has been published in high-impact SCI-indexed journals, advancing knowledge in tumor biology, immunotherapy, and metabolic regulation. Dr. Zhou’s research has directly informed innovative diagnostic and therapeutic strategies, demonstrating a commitment to improving liver cancer outcomes. Their contributions reflect a strong dedication to scientific excellence and medical advancement.

Profile

Scopus

Early Academic Pursuits 🎓

Dr. Suiqing Zhou embarked on an academic journey with a deep-rooted passion for medical sciences, particularly in hepatology and translational cancer research. During their undergraduate years, Dr. Zhou demonstrated exceptional aptitude in biomedical sciences, excelling in coursework and laboratory research. Their keen interest in understanding the complexities of liver diseases led them to pursue advanced studies at Nanjing Medical University, a premier institution known for cutting-edge medical research.

With a strong foundation in clinical medicine and biomedical research, Dr. Zhou continued to expand their expertise by engaging in rigorous doctoral studies. Their PhD research primarily focuses on unraveling the molecular mechanisms of hepatocellular carcinoma (HCC), one of the deadliest forms of liver cancer. By integrating clinical observations with laboratory-based investigations, Dr. Zhou has contributed to significant breakthroughs in understanding cancer metabolism and therapeutic resistance.

Professional Endeavors 💼

As a clinician-scientist, Dr. Zhou seamlessly bridges the gap between medical practice and scientific inquiry. While undergoing extensive clinical training, they also immersed themselves in high-impact research projects, gaining recognition as a Principal Investigator and key contributor to several national and provincial-level research initiatives.

Dr. Zhou’s expertise extends beyond traditional clinical practice; they have played a pivotal role in advancing translational medicine by incorporating cutting-edge technologies such as CRISPR gene editing, omics-based studies, and immune profiling. Their ability to translate laboratory findings into potential therapeutic strategies has led to collaborations with leading hepatology research centers and biotechnology firms.

Contributions and Research Focus 🎡

Dr. Zhou’s research is primarily centered on elucidating the biological pathways that drive hepatocellular carcinoma progression. Key areas of investigation include:

  • Cancer Metabolism and Fatty Acid Biosynthesis: Their research on eIF3f-mediated fatty acid biosynthesis remodeling has provided new insights into tumor malignancy and potential metabolic targets for therapy.
  • Tumor Angiogenesis and Immune Evasion: By studying the role of DGKG in endothelial cells, Dr. Zhou has identified critical mechanisms underlying HCC’s ability to evade immune responses and sustain aggressive growth.
  • Ferroptosis Sensitivity and Immunotherapy Augmentation: Through CRISPR/Cas9 screening, Dr. Zhou’s team has pinpointed TRIM34 as a crucial regulator of ferroptosis sensitivity, paving the way for novel combination therapies to enhance immunotherapy efficacy.
  • Biomarker Discovery and Personalized Medicine: Their research on GFPT2 and CRTC2 as novel biomarkers has opened new avenues for early diagnosis and tailored treatment approaches in HCC.

Dr. Zhou’s impressive publication record (9 SCI-indexed articles) in top-tier journals, including Journal of Hepatology, Cancer Letters, British Journal of Cancer, and Cell Metabolism, underscores the impact of their research in the global scientific community.

Accolades and Recognition 🏆

Dr. Zhou’s contributions to liver cancer research have been met with well-deserved recognition. Their innovative work has led to one published patent (ZL 2021 1 0367998.9, China), signifying their role in developing novel diagnostic and therapeutic solutions.

Beyond research, Dr. Zhou has been actively involved in academic publishing as an editorial board member, further solidifying their reputation as a thought leader in oncology and translational medicine. Invitations to review manuscripts for prestigious medical journals highlight their expertise and influence in the field.

Impact and Influence 🔄

The impact of Dr. Zhou’s research extends beyond publications and patents—it has directly contributed to the refinement of clinical protocols for liver cancer management. Their findings have influenced treatment guidelines and inspired ongoing clinical trials aimed at improving patient outcomes.

Additionally, Dr. Zhou’s role as a mentor and educator has fostered the next generation of medical researchers. By engaging in academic teaching and research supervision, they have guided young scholars in navigating complex biomedical challenges, ensuring a legacy of scientific excellence.

Legacy and Future Contributions 💡

Looking ahead, Dr. Zhou aspires to expand their research on precision oncology, integrating AI-driven diagnostics and targeted therapies into hepatology. Their future endeavors include:

  • Developing Next-Generation Biomarker Panels: Enhancing early detection strategies for liver cancer through advanced molecular profiling.
  • Exploring AI-Driven Drug Discovery: Utilizing artificial intelligence to identify novel drug targets and optimize personalized treatment plans.
  • Expanding Global Collaborations: Partnering with leading hepatology research institutions to accelerate translational research efforts.

Dr. Zhou’s relentless pursuit of knowledge and unwavering commitment to medical innovation position them as a driving force in the field of liver cancer research. With a distinguished career marked by scientific breakthroughs and impactful contributions, their work continues to inspire hope for improved cancer treatments and patient care worldwide.

Publication Top Notes

Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma. Journal of Hepatology

Author: Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, Dai J, Yu K, Zhang Y, Baheti T, Pu L, Xu J, Qian X, Zhang C, Xia Y, Dai X, Li Q, Wang X.

Journal: Journal of Hepatology

Year: 2024

Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma

Author: Y., Gao, Yun, X., Chen, Xiaoyun, Y., Zhu, Yuerong, L., Pu, Liyong, X., Wang, Xuehao

Journal: Human Cell

Year: 2025



	

Sydney Thai | Geriatric Oncology | Best Researcher Award

Dr. Sydney Thai | Geriatric Oncology | Best Researcher Award

Post-Doctoral Fellow at CERobs Consulting, United States.

Sydney Thai is a dedicated epidemiologist and researcher specializing in pharmacoepidemiology and real-world evidence. They earned a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill, preceded by an M.S. in Nutrition from Columbia University and a B.S. in Human Biology from Cornell University. Sydney’s doctoral dissertation focused on frailty screening and impairment patterns in older adults with cancer, using the CARE Registry. Throughout their career, Sydney has held influential roles at organizations like Bristol Myers Squibb and CERobs Consulting, LLC, contributing extensively to studies in aging, oncology, and dermatology. They are recognized for their expertise in healthcare databases, pharmacovigilance, and epidemiological methods. Sydney has also excelled in academia, serving as a teaching assistant and tutor at UNC Chapel Hill and DePaul University, respectively.

Professional Profiles:

Education

Sydney Thai pursued an extensive academic journey culminating in a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill, completed between 2014 and 2022. His doctoral dissertation focused on “Frailty Screening and Impairment Patterns in Older Adults with Cancer” utilizing data from the Cancer Aging and Resilience Evaluation (CARE) Registry. Prior to his doctoral studies, Sydney completed a Master of Science in Nutrition at Columbia University in 2012, where his thesis explored the role of vitamin A in pancreatic development using embryonic mouse models. He also engaged in graduate studies at DePaul University from 2013 to 2014, delving into Geography, Psychology, Public Health, and Marketing, achieving a GPA of 3.95. Sydney’s academic journey began with a Bachelor of Science in Human Biology, Health & Society from Cornell University, where he graduated in 2011 with a GPA of 3.53, setting a foundation for his subsequent academic achievements and research endeavors in epidemiology and public health.

Professional Experience

Sydney Thai has built a robust professional career marked by significant roles in research and academia. Currently serving as a Post-doctoral Fellow at CERobs Consulting, LLC since 2022, Sydney specializes in real-world data (RWD), real-world evidence (RWE), and Pharmacoepidemiology. Previously, from 2020 to 2022, he held a Pre-doctoral Research Fellowship at Bristol Myers Squibb, focusing on Worldwide Health Economics and Outcomes Research in Immunology, specifically Dermatology and Rheumatology. Prior to this, Sydney worked as a Graduate Research Assistant at CERobs Consulting, LLC from 2018 to 2020, contributing to research in pharmacotherapeutic areas such as biologics, anticholinergic therapies, and opioid treatments. He also gained valuable experience as a Summer Pharmacoepidemiology Intern at Research Triangle Institute (RTI) Health Solutions in 2018. Sydney’s commitment to epidemiology and public health is further evidenced by his teaching and tutoring roles at the University of North Carolina at Chapel Hill, where he assisted in Epidemiology courses and provided academic support. His professional journey underscores a dedication to advancing healthcare research and epidemiological practices.

Teaching Experience

Sydney Thai brings a wealth of academic experience and expertise across multiple institutions. With a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill, Sydney has served as a dedicated educator and mentor. At UNC Chapel Hill, Sydney excelled as an Academic Enrichment Program Tutor in Epidemiology, guiding students through complex concepts from Fall 2015 to Spring 2019. Sydney’s teaching portfolio also includes roles as a Teaching Assistant for Principles of Epidemiology and Human Development at UNC Chapel Hill and various positions at DePaul University, where Sydney taught courses in psychology and social justice. Beginning at Cornell University, Sydney’s career in education blossomed, culminating in impactful roles as Head Teaching Assistant and Teaching Assistant, demonstrating a deep commitment to fostering learning environments and supporting student growth in public health, psychology, and nutrition disciplines.

Award and Honors

Sydney Thai has excelled in academia and received numerous prestigious honors and awards throughout their educational and professional career. They received the International Society for Pharmacoepidemiology (ISPE) Scholarship to attend the 34th International Conference for Pharmacoepidemiology in Prague, Czech Republic, showcasing their commitment to advancing pharmacoepidemiology globally. At the University of North Carolina at Chapel Hill, Sydney was recognized with the Sidney Kark Award for Distinguished Teaching Assistant in Epidemiology, underscoring their dedication to teaching and mentorship. Their academic prowess was also recognized at DePaul University with the Geography Map of the Month award for their project on “Mapping Pregnancy and Socio-economic Variables Across Chicago.” Additionally, Sydney was inducted into the Order of Omega Greek Leadership Honor Society and named a Meinig Family Cornell National Scholar during their tenure at Cornell University, where they consistently achieved Dean’s List honors. These accolades highlight Sydney’s leadership, academic excellence, and contributions to public health and epidemiology.

Publications

  1. Geriatric Assessment Impairment Profiles and Mortality in Older Adults With Gastrointestinal Cancers: Latent Class Analysis of the CARE Registry
    • Authors: Thai, S.T., Lund, J.L., Kenzik, K.M., Al-Obaidi, M., Williams, G.R.
    • Year: 2024
    • Citations: 0
  2. Epidemiology and clinical characteristics of interstitial lung disease in patients with rheumatoid arthritis from the JointMan database
    • Authors: Zhuo, J., Lama, S., Knapp, K., Thai, S., Craig, G.L.
    • Year: 2023
    • Citations: 4
  3. Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey
    • Authors: Thai, S., Barlow, S., Lucas, J., Zhuo, J., Wu, J.J.
    • Year: 2023
    • Citations: 0
  4. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies
    • Authors: Thai, S., Zhuo, J., Zhong, Y., Priya, L., Wu, J.J.
    • Year: 2023
    • Citations: 5
  5. A systematic review of the patient burden of Crohn’s disease-related rectovaginal and anovaginal fistulas
    • Authors: Iglay, K., Bennett, D., Kappelman, M.D., Karki, C., Cook, S.F.
    • Year: 2022
    • Citations: 2
  6. Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
    • Authors: Zhao, Y., Zhang, J., Zheng, K., Stürmer, T., Wang, T.
    • Year: 2022
    • Citations: 12
  7. Re: Increased Risk of Incident Dementia following Use of Anticholinergic Agents: A Systematic Literature Review and Meta-Analysis
    • Authors: Dmochowski, R.R., Thai, S., Iglay, K., Mudd, P.N., Poole, C.
    • Year: 2022
    • Citations: 0
  8. Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
    • Authors: Guo, M., Thai, S., Zhou, J., Wang, T., Cui, X.
    • Year: 2021
    • Citations: 5
  9. Re: Increased Risk of Incident Dementia following Use of Anticholinergic Agents: A Systematic Literature Review and Meta-Analysis
    • Authors: Dmochowski, R.R., Thai, S., Iglay, K., Mudd, P.N., Poole, C.
    • Year: 2021
    • Citations: 0
  10. Assessing clinical trial effects on outcomes among pediatric and adolescent and young adult (AYA) patients with cancer
    • Authors: Shmuel, S., Yang, J.Y., Thai, S., Webster-Clark, M., Lund, J.L.
    • Year: 2021
    • Citations: 0